(Q35179411)

7 August 2017

1 reference

title

Gefitinib (Iressa) trials in non-small cell lung cancer (English)

1 reference

7 August 2017

1 reference

David H Johnson

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

41 Suppl 1

1 reference

7 August 2017

page(s)

S23-8

1 reference

Untangling the ErbB signalling network

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Tyrosine kinase inhibitors-ZD1839 (Iressa).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Epidermal growth factor receptor family in lung cancer and premalignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Treatment of advanced non-small-cell lung cancer with two-drug combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Influence of unrecognized molecular heterogeneity on randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Clinical trial designs for cytostatic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

Randomized discontinuation design: application to cytostatic antineoplastic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900136-3

7 January 2021

10.1016/S0169-5002(03)00136-3

Identifiers

DOI

1 reference

7 August 2017

1 reference